Considering the pivotal role of the DCAF12‐TRiC/CCT axis in cytoskeletal dynamics and the regulation of oncogenic pathways, such as YAP, STAT3, and mTOR, in lung cancer cells, we investigated the therapeutic potential of HSF1A, a novel small‐molecule inhibitor of the TRiC/CCT complex.[55] After treating cells with HSF1A for 18 h, we observed dose‐dependent inhibition of migration in H1299 and 889DTC cells (Figure7A). Here, MARVELD2 is linked to lung carcinoma.